Registry to evaluate secretoneurin in predicting atrial fibrillation recurrence
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
NA · University Hospital Ostrava · NCT05794464
This study is testing if measuring a substance called secretoneurin in the blood can help predict whether people with atrial fibrillation will have their heart rhythm problems come back after treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Ostrava (other) |
| Locations | 1 site (Ostrava, Moravian-Silesian Region) |
| Trial ID | NCT05794464 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the levels of secretoneurin (SN) and other biomarkers before and after catheter ablation or electrical cardioversion in patients with atrial fibrillation (Afib). By analyzing these biomarkers, the study seeks to predict the likelihood of Afib recurrence following these interventions. Blood samples will be collected from participants before and after the procedures, and they will be monitored for recurrence using ECG Holter and external loop recorders. The study focuses on understanding the relationship between these biomarkers and Afib outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with paroxysmal or persistent atrial fibrillation who are indicated for catheter ablation or electrical cardioversion.
Not a fit: Patients with longstanding or permanent atrial fibrillation, severe heart or kidney conditions, or recent myocardial infarction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for predicting Afib recurrence, potentially improving patient management and outcomes.
How similar studies have performed: While the approach of using biomarkers to predict Afib recurrence is being explored, this specific combination of biomarkers and methodology appears to be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Atrial fibrillation (Afib); (paroxysmal, persistent) * Patients indicated for catheter ablation and/or electrical cardioversion * Signed informed consent Exclusion Criteria: * Longstanding or permanent atrial fibrillation * Severe mitral regurgitation * Heart failure with a permanently reduced ejection fraction * Cerebral ischaemic stroke in \< 3 months * Severe kidney injury * Severe renal insufficiency * Hepatic insufficiency limiting biomarker sampling * Myocardial infarction \< 3 months
Where this trial is running
Ostrava, Moravian-Silesian Region
- University Hospital Ostrava — Ostrava, Moravian-Silesian Region, Czechia (RECRUITING)
Study contacts
- Principal investigator: Jiří Plášek, MD,PhD,FESC — University Hospital Ostrava
- Study coordinator: Jiří Hynčica
- Email: jiri.hyncica@fno.cz
- Phone: 0042059737
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation, Paroxysmal or Persistent, atrial fibrillation, secretoneurin, catheter ablation, electrical cardio version